Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease
Study Type
OBSERVATIONAL
Enrollment
48
Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
Hôpital Huriez
Lille, France
Centre Hospitalier Universitaire Hôtel-Dieu de Nantes
Nantes, France
Centre Hospitalier Lyon Sud
Pierre Bénité, France
Quantification of residual disease
study the sensitivity of the method of quantification of circulating tumor cells compared to 2 others methods of detection
Time frame: Residual disease is assessed up to 18 months after inclusion
kinetic of variation of the residual tumor cells detected by flow cytometry method
% positive cells in bone marrow sample
Time frame: 18 months
kinetic of variation of the residual tumor cells detected by new generation sequencing method
% positive in bone marrow sample
Time frame: 18 months
kinetic of variation of the circulating tumor cells
number of cells / mL of blood
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.